Hong-Chen He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hong-Chen He has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Xi Yu
Department of Rehabilitation, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
10 shared publications- Xiao-Na Xiang
West China Hospital, Sichuan University
10 shared publications Xiao-Na Xiang
Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, China
7 shared publications- Chengqi He
Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University
6 shared publications Qian Wang
Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Chengdu 610041, Sichuan Province, China
6 shared publications- Jiang-Yin Zhang
Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, P. R. China
5 shared publications
Latest Publications
- 24 August 2026
- Published by Wiley in Arthroscopy
- Vol. 42 (10) , 2275-2290
Bone Marrow‐Derived Cell Therapy Plus Core Decompression Enhanced Efficacy Compared With Core Decompression Alone in Treating Osteonecrosis of the Femoral Head: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Purpose: To systematically determine whether bone marrow‐derived cell therapy combined with core decompression could result in better improvements in pain relief, function, and radiographic progression, higher survival of hip joints, and an equivalent rate of adverse events than hip‐preserving techniques alone in individuals with osteonecrosis of the femoral head (ONFH). Methods: We searched randomized controlled trials of core decompression with or without cell‐based therapy in osteonecrosis of the femoral head across MEDLINE, the Cochrane Central Register of Controlled Clinical Trials, PubMed, Embase, Web of Science, and the Physiotherapy Evidence Database from inception to April 2025. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) of outcomes were reported. The pooled data with sensitivity analysis and subgroup analysis were conducted via RevMan 5.4. Results: Ten studies with 460 participants (530 hips) were included. The results revealed that cell therapy plus core decompression improved pain relief (SMD: −1.30; 95% CI: −2.21 to −0.38), hip function (SMD: −1.79; 95% CI: −1.79 to −0.90), and survival of hip joints (RR: 0.47; 95% CI: 0.27‐0.82) better than core decompression alone. No differences in radiographic progression (RR: 0.34; 95% CI: 0.08‐1.47; SMD: −1.02; 95% CI: −2.70 to 0.65) or adverse events (RR: 2.13; 95% CI: 0.29‐15.42) were observed between groups. Conclusions: The combination of bone marrow‐derived cell therapy with core decompression may be better for pain relief, function, and survival of joints for osteonecrosis of the femoral head than core decompression alone but remains limited and heterogeneous. Additionally, there was no difference in adverse events and radiographic progression between groups. Level of Evidence: Level I, meta‐analyses of randomized controlled trials.
- 24 August 2026
- Published by Wiley in Arthroscopy
- Vol. 42 (10) , 2275-2290
Bone Marrow‐Derived Cell Therapy Plus Core Decompression Enhanced Efficacy Compared With Core Decompression Alone in Treating Osteonecrosis of the Femoral Head: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Purpose: To systematically determine whether bone marrow‐derived cell therapy combined with core decompression could result in better improvements in pain relief, function, and radiographic progression, higher survival of hip joints, and an equivalent rate of adverse events than hip‐preserving techniques alone in individuals with osteonecrosis of the femoral head (ONFH). Methods: We searched randomized controlled trials of core decompression with or without cell‐based therapy in osteonecrosis of the femoral head across MEDLINE, the Cochrane Central Register of Controlled Clinical Trials, PubMed, Embase, Web of Science, and the Physiotherapy Evidence Database from inception to April 2025. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) of outcomes were reported. The pooled data with sensitivity analysis and subgroup analysis were conducted via RevMan 5.4. Results: Ten studies with 460 participants (530 hips) were included. The results revealed that cell therapy plus core decompression improved pain relief (SMD: −1.30; 95% CI: −2.21 to −0.38), hip function (SMD: −1.79; 95% CI: −1.79 to −0.90), and survival of hip joints (RR: 0.47; 95% CI: 0.27‐0.82) better than core decompression alone. No differences in radiographic progression (RR: 0.34; 95% CI: 0.08‐1.47; SMD: −1.02; 95% CI: −2.70 to 0.65) or adverse events (RR: 2.13; 95% CI: 0.29‐15.42) were observed between groups. Conclusions: The combination of bone marrow‐derived cell therapy with core decompression may be better for pain relief, function, and survival of joints for osteonecrosis of the femoral head than core decompression alone but remains limited and heterogeneous. Additionally, there was no difference in adverse events and radiographic progression between groups. Level of Evidence: Level I, meta‐analyses of randomized controlled trials.
- Open Access
- 21 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Extracellular vesicles in osteoarthritis: pathological mechanisms, regenerative therapies and clinical translation
- 21 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessExtracellular vesicles in osteoarthritis: pathological mechanisms, regenerative therapies and clinical translation
- 26 January 2026
- Published by SAGE Publications in The American Journal of Sports Medicine
- Vol. 54 (4) , 831-847
Effects of Platelet-Rich Plasma on Chondrocyte Senescence and Knee Osteoarthritis Progression
Background: Knee osteoarthritis (KOA) is a common degenerative disease characterized by cartilage degradation and damage. Chondrocyte senescence plays a key role in disease progression, as the accumulation of senescent cells disrupts cellular function and exacerbates cartilage damage. Platelet-rich plasma (PRP), rich in growth factors, promotes tissue repair and regeneration. It remains unclear whether platelet-rich plasma modulates cellular senescence to regulate the progression of knee osteoarthritis. Purpose: To evaluate the effects of PRP on chondrocyte senescence in KOA and investigate its potential underlying mechanisms. Study Design: Controlled laboratory study. Methods: Chondrocyte cell cycle, senescence markers, senescence-associated secretory phenotype secretion, and extracellular matrix integrity were evaluated by Western blot, real-time quantitative polymerase chain reaction, flow cytometry, immunofluorescence, and β-galactosidase staining. Mitochondrial function and antioxidative properties were assessed by measuring mitochondrial membrane potential and reactive oxygen species levels. Additionally, a rat KOA model was established by anterior cruciate ligament transection, followed by weekly intra-articular injections of PRP or phosphate-buffered saline for 4 weeks. Knee joint samples were collected at 8 and 12 weeks after surgery for gross morphology, imaging, and histological analysis. Results: In vitro experiments revealed that PRP inhibited chondrocyte senescence and extracellular matrix degeneration, as evidenced by increased expression of collagen type 2 alpha 1 (COL2A1) and aggrecan (ACAN), and decreased expression of matrix metalloproteinase 13 (MMP13), a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), cyclin-dependent kinase inhibitor 2A (P16), cyclin-dependent kinase inhibitor 1A (P21), and tumor protein p53 (P53). Additionally, messenger ribonucleic acid (mRNA) expression of interleukin-1β (Il1b), interleukin-6 (Il6), and tumor necrosis factor (TNF), as well as β-galactosidase positivity, was suppressed. Furthermore, PRP was found to modulate cell cycle arrest, improve mitochondrial function, and enhance antioxidative properties. In vivo experiments demonstrated that intra-articular PRP injection repaired damaged articular cartilage, improved trabecular bone parameters, and upregulated the expression of COL2A1 and ACAN, while suppressing the expression of senescence-related proteins P16, P21, and P53 in the cartilage of the KOA model. Conclusion: Our results demonstrated that PRP may slow osteoarthritis progression by inhibiting chondrocyte senescence. Clinical Relevance: Chondrocyte senescence plays a critical role in the pathogenesis of osteoarthritis. This study provides new theoretical foundations and experimental support for the clinical application of PRP in the treatment of osteoarthritis.
- 26 January 2026
- Published by SAGE Publications in The American Journal of Sports Medicine
- Vol. 54 (4) , 831-847
Effects of Platelet-Rich Plasma on Chondrocyte Senescence and Knee Osteoarthritis Progression
Background: Knee osteoarthritis (KOA) is a common degenerative disease characterized by cartilage degradation and damage. Chondrocyte senescence plays a key role in disease progression, as the accumulation of senescent cells disrupts cellular function and exacerbates cartilage damage. Platelet-rich plasma (PRP), rich in growth factors, promotes tissue repair and regeneration. It remains unclear whether platelet-rich plasma modulates cellular senescence to regulate the progression of knee osteoarthritis. Purpose: To evaluate the effects of PRP on chondrocyte senescence in KOA and investigate its potential underlying mechanisms. Study Design: Controlled laboratory study. Methods: Chondrocyte cell cycle, senescence markers, senescence-associated secretory phenotype secretion, and extracellular matrix integrity were evaluated by Western blot, real-time quantitative polymerase chain reaction, flow cytometry, immunofluorescence, and β-galactosidase staining. Mitochondrial function and antioxidative properties were assessed by measuring mitochondrial membrane potential and reactive oxygen species levels. Additionally, a rat KOA model was established by anterior cruciate ligament transection, followed by weekly intra-articular injections of PRP or phosphate-buffered saline for 4 weeks. Knee joint samples were collected at 8 and 12 weeks after surgery for gross morphology, imaging, and histological analysis. Results: In vitro experiments revealed that PRP inhibited chondrocyte senescence and extracellular matrix degeneration, as evidenced by increased expression of collagen type 2 alpha 1 (COL2A1) and aggrecan (ACAN), and decreased expression of matrix metalloproteinase 13 (MMP13), a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), cyclin-dependent kinase inhibitor 2A (P16), cyclin-dependent kinase inhibitor 1A (P21), and tumor protein p53 (P53). Additionally, messenger ribonucleic acid (mRNA) expression of interleukin-1β (Il1b), interleukin-6 (Il6), and tumor necrosis factor (TNF), as well as β-galactosidase positivity, was suppressed. Furthermore, PRP was found to modulate cell cycle arrest, improve mitochondrial function, and enhance antioxidative properties. In vivo experiments demonstrated that intra-articular PRP injection repaired damaged articular cartilage, improved trabecular bone parameters, and upregulated the expression of COL2A1 and ACAN, while suppressing the expression of senescence-related proteins P16, P21, and P53 in the cartilage of the KOA model. Conclusion: Our results demonstrated that PRP may slow osteoarthritis progression by inhibiting chondrocyte senescence. Clinical Relevance: Chondrocyte senescence plays a critical role in the pathogenesis of osteoarthritis. This study provides new theoretical foundations and experimental support for the clinical application of PRP in the treatment of osteoarthritis.
- 22 January 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 74, 244-255
Global research trends, evolution, and future directions on platelet-rich plasma in surgery: A bibliometric analysis
- 22 January 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 74, 244-255
Global research trends, evolution, and future directions on platelet-rich plasma in surgery: A bibliometric analysis
- 1 January 2026
- Published by e-Century Publishing Corporation in American Journal of Translational Research
- Vol. 18 (5) , 4063-4069
Effects of dexmedetomidine on the prevention of nausea and vomiting in children after upper limb fracture surgery
Objective: To investigate the effect of dexmedetomidine on the prevention of postoperative nausea and vomiting (PONV) in children undergoing upper limb fracture surgery. Methods: A total of 82 children undergoing upper limb fracture surgery were divided into either a control group, which received general anesthesia plus brachial plexus block, or a study group, which received additional dexmedetomidine. The incidence of nausea and vomiting, postoperative agitation, perioperative hemodynamic parameters, stress-related indicators, Visual Analogue Scale (VAS) scores, and perioperative conditions were compared between the two groups. Results: The incidences of nausea and vomiting, postoperative agitation, and the postoperative VAS scores were significantly lower in the study group than in the control group. Compared with baseline values at T0, the levels of malondialdehyde, norepinephrine, epinephrine, and cortisol increased in both groups; however, these increases were significantly lower in the study group than in the control group. In addition, the onset time of anesthesia, awakening time, and post-anesthesia care unit (PACU) stay were all shorter in the study group than in the control group. Conclusions: The use of dexmedetomidine in children undergoing upper limb fracture surgery can attenuate perioperative hemodynamic fluctuations and stress reactions, alleviate postoperative pain, shorten awakening time, and reduce the incidence of postoperative nausea and vomiting.
- 1 January 2026
- Published by e-Century Publishing Corporation in American Journal of Translational Research
- Vol. 18 (5) , 4063-4069
Effects of dexmedetomidine on the prevention of nausea and vomiting in children after upper limb fracture surgery
Objective: To investigate the effect of dexmedetomidine on the prevention of postoperative nausea and vomiting (PONV) in children undergoing upper limb fracture surgery. Methods: A total of 82 children undergoing upper limb fracture surgery were divided into either a control group, which received general anesthesia plus brachial plexus block, or a study group, which received additional dexmedetomidine. The incidence of nausea and vomiting, postoperative agitation, perioperative hemodynamic parameters, stress-related indicators, Visual Analogue Scale (VAS) scores, and perioperative conditions were compared between the two groups. Results: The incidences of nausea and vomiting, postoperative agitation, and the postoperative VAS scores were significantly lower in the study group than in the control group. Compared with baseline values at T0, the levels of malondialdehyde, norepinephrine, epinephrine, and cortisol increased in both groups; however, these increases were significantly lower in the study group than in the control group. In addition, the onset time of anesthesia, awakening time, and post-anesthesia care unit (PACU) stay were all shorter in the study group than in the control group. Conclusions: The use of dexmedetomidine in children undergoing upper limb fracture surgery can attenuate perioperative hemodynamic fluctuations and stress reactions, alleviate postoperative pain, shorten awakening time, and reduce the incidence of postoperative nausea and vomiting.
- Open Access
- 29 October 2025
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 16, 1678037
Platelet-rich plasma improves pain and function in knee osteoarthritis: a retrospective study
Introduction: This study aimed to evaluate the efficacy of platelet-rich plasma (PRP) in treating knee osteoarthritis (KOA) and the effects of baseline characteristics and PRP intervention parameters on treatment outcomes. Methods: Overall, 140 individuals diagnosed with KOA who received PRP injections and completed a 6-month follow-up period were enrolled in this retrospective analysis. Knee pain and functional outcomes were assessed using the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Based on the Minimal Clinically Important Difference (MCID) in outcomes, the participants were divided into effective and ineffective groups. Using multivariable logistic regression to explore factors influencing treatment outcomes, we compared the effective and ineffective groups to identify predictors of response to PRP therapy. Results: At 6 months, the median (IQR) VAS score significantly decreased from 66.5 (27) to 24 (34) (95% CI = −38 to −30.5), p < 0.001), and WOMAC scores improved from 29 (22) to 12 (14) (95% CI = −16.5 to −12), p < 0.001). Five mild adverse events were reported. Multivariate analysis indicated that only the number of injections significantly influenced VAS outcomes (OR = 4.285, 95% CI: 1.586–11.578, p = 0.004). Regarding WOMAC, multivariate analysis revealed that body mass index (BMI) (OR = 0.867, 95% CI: 0.755–0.995, p = 0.042) and disease duration (OR = 0.905, 95% CI: 0.784–0.989, p = 0.045) significantly affected outcomes. Age, sex, Kellgren-Lawrence (KL) grade, number of PRP injections, and injection frequency did not significantly impact WOMAC scores. Conclusion: PRP therapy is a safe and effective treatment option for KOA. In this 6-month follow-up investigation, we observed that the number of injections administered affected pain levels, while disease duration and BMI affected knee joint function. Insights from this study may facilitate patient selection and PRP treatment protocol optimization in clinical practice.
- 29 October 2025
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 16, 1678037
Open AccessPlatelet-rich plasma improves pain and function in knee osteoarthritis: a retrospective study
Introduction: This study aimed to evaluate the efficacy of platelet-rich plasma (PRP) in treating knee osteoarthritis (KOA) and the effects of baseline characteristics and PRP intervention parameters on treatment outcomes. Methods: Overall, 140 individuals diagnosed with KOA who received PRP injections and completed a 6-month follow-up period were enrolled in this retrospective analysis. Knee pain and functional outcomes were assessed using the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Based on the Minimal Clinically Important Difference (MCID) in outcomes, the participants were divided into effective and ineffective groups. Using multivariable logistic regression to explore factors influencing treatment outcomes, we compared the effective and ineffective groups to identify predictors of response to PRP therapy. Results: At 6 months, the median (IQR) VAS score significantly decreased from 66.5 (27) to 24 (34) (95% CI = −38 to −30.5), p < 0.001), and WOMAC scores improved from 29 (22) to 12 (14) (95% CI = −16.5 to −12), p < 0.001). Five mild adverse events were reported. Multivariate analysis indicated that only the number of injections significantly influenced VAS outcomes (OR = 4.285, 95% CI: 1.586–11.578, p = 0.004). Regarding WOMAC, multivariate analysis revealed that body mass index (BMI) (OR = 0.867, 95% CI: 0.755–0.995, p = 0.042) and disease duration (OR = 0.905, 95% CI: 0.784–0.989, p = 0.045) significantly affected outcomes. Age, sex, Kellgren-Lawrence (KL) grade, number of PRP injections, and injection frequency did not significantly impact WOMAC scores. Conclusion: PRP therapy is a safe and effective treatment option for KOA. In this 6-month follow-up investigation, we observed that the number of injections administered affected pain levels, while disease duration and BMI affected knee joint function. Insights from this study may facilitate patient selection and PRP treatment protocol optimization in clinical practice.
- Open Access
- 26 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 13 (27) , 108998
Ultrasound-guided platelet-rich plasma injection improves pain, function and symmetry in lumbar myofascial pain syndrome: A case report
BACKGROUND Myofascial pain syndrome (MPS) is a common musculoskeletal disease associated with myofascial trigger point (MTrP). Muscle injury is one of the common causes of MPS. Currently, there is no effective treatment for MPS. CASE SUMMARY A 24-year-old female with chronic lower back MPS secondary to quadratus lumborum (QL) injury underwent comprehensive evaluation using validated scales: Pain severity (visual analog scale, McGill Pain Questionnaire), functional disability (Oswestry Disability Index, Roland Morris Disability Questionnaire), and quality of life [short form 36 (SF-36)]. Objective assessments included sEMG of bilateral QL muscles, Myoton mechanical property analysis, and magnetic resonance imaging volumetric measurements. The patient received four ultrasound-guided platelet-rich plasma (PRP) injections at 4-week intervals, with follow-up evaluations conducted at 1, 3, and 6 months post-treatment. CONCLUSION Ultrasound-guided PRP injections alleviated pain, restored function, and improved quality of life in post-traumatic MPS. sEMG demonstrated neuromuscular symmetry restoration in MTrP-affected muscles, supporting the therapeutic potential of PRP.
- 26 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 13 (27) , 108998
Open AccessUltrasound-guided platelet-rich plasma injection improves pain, function and symmetry in lumbar myofascial pain syndrome: A case report
BACKGROUND Myofascial pain syndrome (MPS) is a common musculoskeletal disease associated with myofascial trigger point (MTrP). Muscle injury is one of the common causes of MPS. Currently, there is no effective treatment for MPS. CASE SUMMARY A 24-year-old female with chronic lower back MPS secondary to quadratus lumborum (QL) injury underwent comprehensive evaluation using validated scales: Pain severity (visual analog scale, McGill Pain Questionnaire), functional disability (Oswestry Disability Index, Roland Morris Disability Questionnaire), and quality of life [short form 36 (SF-36)]. Objective assessments included sEMG of bilateral QL muscles, Myoton mechanical property analysis, and magnetic resonance imaging volumetric measurements. The patient received four ultrasound-guided platelet-rich plasma (PRP) injections at 4-week intervals, with follow-up evaluations conducted at 1, 3, and 6 months post-treatment. CONCLUSION Ultrasound-guided PRP injections alleviated pain, restored function, and improved quality of life in post-traumatic MPS. sEMG demonstrated neuromuscular symmetry restoration in MTrP-affected muscles, supporting the therapeutic potential of PRP.
- Open Access
- 4 July 2025
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 26 (1) , 1-9
Ultrasound-guided injection of platelet-rich plasma alleviated pain and improved function for individuals with myofascial pain syndrome: a retrospective case series study
Myofascial pain syndrome (MPS) is a regional musculoskeletal pain associated with myofascial trigger point (MTrP), lacks therapies with sustained efficacy. Current modalities offer short-term relief but fail to address underlying tissue degeneration. This study aimed to evaluate the 3-month safety and efficacy of ultrasound-guided platelet-rich plasma (PRP) injections in alleviating MPS-related pain and function. From January 2023 to April 2023, we selected 71 eligible individuals with MPS who received PRP treatment of the upper trapezius, rhomboid, erector spinae, and quadratus lumborum in the Department of Rehabilitation Medicine, West China Hospital, Sichuan University, a retrospective case series study. Primary outcome was pain quantified by the Visual Analog Scale (VAS) and the McGill Pain Questionnaire (McGill). Secondary outcomes were region-specific functional improvement evaluated using the Neck Disability Index (NDI) for cervical pathology and the Oswestry Disability Index (ODI) for lumbar conditions, with additional assessment via the Roland Morris Disability Questionnaire (RMDQ), and quality of life measured by the Medical Outcomes Short Form-36 (SF-36). These parameters were evaluated at baseline and 24 h, 2 weeks, 1 month, and 3 months post-treatment. The cohort included 71 individuals (mean age 47.6 ± 15.9 years; 71.8% female) with chronic MPS. The pain VAS decreased from 5.0 [4.0–6.0] at baseline to 1.0 [1.0–2.0] at 3 months (p < 0.001), with the McGill decreased from 11.0 [8.0–15.0] to 2.0 [2.0–5.0] (p < 0.001). The NDI decreased from 42.0 [29.3–53.3] at baseline to 9.5 [5.0–11.0] (p < 0.001). The ODI declined from 22.0 [14.0–29.0] to 10.0 [6.0–14.0] (p < 0.001). The RMDQ showed improvement, from 10.0 [6.5–16.0] to 4.0 [2.0–5.0] (p < 0.001). Similarly, the SF-36 score was obviously improved 3 months post-treatment of PRP (p < 0.01). No adverse reactions were reported during follow-up. Ultrasound-guided platelet-rich plasma treatment could significantly alleviate the pain and improve the physical function and quality of life in the individuals with myofascial pain syndrome during 3-months follow-up.
- 4 July 2025
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 26 (1) , 1-9
Open AccessUltrasound-guided injection of platelet-rich plasma alleviated pain and improved function for individuals with myofascial pain syndrome: a retrospective case series study
Myofascial pain syndrome (MPS) is a regional musculoskeletal pain associated with myofascial trigger point (MTrP), lacks therapies with sustained efficacy. Current modalities offer short-term relief but fail to address underlying tissue degeneration. This study aimed to evaluate the 3-month safety and efficacy of ultrasound-guided platelet-rich plasma (PRP) injections in alleviating MPS-related pain and function. From January 2023 to April 2023, we selected 71 eligible individuals with MPS who received PRP treatment of the upper trapezius, rhomboid, erector spinae, and quadratus lumborum in the Department of Rehabilitation Medicine, West China Hospital, Sichuan University, a retrospective case series study. Primary outcome was pain quantified by the Visual Analog Scale (VAS) and the McGill Pain Questionnaire (McGill). Secondary outcomes were region-specific functional improvement evaluated using the Neck Disability Index (NDI) for cervical pathology and the Oswestry Disability Index (ODI) for lumbar conditions, with additional assessment via the Roland Morris Disability Questionnaire (RMDQ), and quality of life measured by the Medical Outcomes Short Form-36 (SF-36). These parameters were evaluated at baseline and 24 h, 2 weeks, 1 month, and 3 months post-treatment. The cohort included 71 individuals (mean age 47.6 ± 15.9 years; 71.8% female) with chronic MPS. The pain VAS decreased from 5.0 [4.0–6.0] at baseline to 1.0 [1.0–2.0] at 3 months (p < 0.001), with the McGill decreased from 11.0 [8.0–15.0] to 2.0 [2.0–5.0] (p < 0.001). The NDI decreased from 42.0 [29.3–53.3] at baseline to 9.5 [5.0–11.0] (p < 0.001). The ODI declined from 22.0 [14.0–29.0] to 10.0 [6.0–14.0] (p < 0.001). The RMDQ showed improvement, from 10.0 [6.5–16.0] to 4.0 [2.0–5.0] (p < 0.001). Similarly, the SF-36 score was obviously improved 3 months post-treatment of PRP (p < 0.01). No adverse reactions were reported during follow-up. Ultrasound-guided platelet-rich plasma treatment could significantly alleviate the pain and improve the physical function and quality of life in the individuals with myofascial pain syndrome during 3-months follow-up.
- Top Cited PapersOpen Access
- 28 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5623-5636
Minimally invasive surgery for lumbar disc herniation: a meta-analysis of efficacy and safety
Objective: Minimally invasive treatment plays a pivotal role in the management of lumbar disc herniation (LDH). Owing to its benefits, including reduced trauma, accelerated recovery, and decreased incidence of complications, it has progressively emerged as the primary approach for treating this condition. The objective of this study was to compare the outcomes observed in patients who underwent various minimally invasive surgical techniques for the treatment of LDH. Study design: Systematic reviews and meta-analyses. Methods: A systematic review was conducted to evaluate and compare the effectiveness of various minimally invasive treatment options for LDH, including percutaneous transforaminal endoscopic discectomy (PTED), microendoscopic discectomy (MED), microscopic discectomy (MD), percutaneous endoscopic interlaminar discectomy (PEID), endoscopic discectomy (ED), full-endoscopic discectomy (FED), percutaneous endoscopic lumbar discectomy (PELD), and PELD combined with platelet-rich plasma (PRP). The outcomes assessed included visual analog scores (VAS) for leg pain and back pain, Japanese Orthopedic Association scores, the Oswestry Disability Index (ODI), 36 physical functioning and bodily pain scores, the EuroQol five-dimensional score, the numeric pain score, the duration of surgery, and the relative risk of reoperation. The collected data were analyzed via a random effects meta-analysis approach. Results: This review analyzed 22 comparative studies with 4068 patients. Compared to MED, PTED had a shorter operative time (64.19 minutes vs. MED’s 66.61 minutes; not significant), less intraoperative blood loss (16.97 vs. 28.55; P < 0.001), and a shorter hospital stay (4.92 days vs. 6.71 days; P < 0.001). MED was associated with a lower postoperative recurrence rate (3.69% vs. 6.08% for PTED). Compared with PTED, PEID was associated with lower ODI (12.69 vs. 15.39; P = 0.77) and VAS scores (1.38 vs. 1.46; P = 0.42). MD significantly decreased intraoperative blood loss (48.63 vs. 64.4 in the ED) and operative time (85.38 vs. 114.65). The combination of PELD and PRP injections provided pain relief and reduced recurrence. Conclusion: Different minimally invasive surgeries for LDH have unique benefits. PTED has advantages in terms of operative time, blood loss, and length of hospital stay. However, there is a risk of nerve damage and cerebrospinal fluid leakage. The recurrence rate of MED is low. PEID is associated with lower ODI and VAS scores. MD reduces blood loss and operative time. The combination of PELD and PRP injections provides a new therapeutic direction for the treatment of LDH by relieving pain, reducing recurrence, improving patient satisfaction, and possibly promoting disc repair.
- 28 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5623-5636
Top Cited PapersOpen AccessMinimally invasive surgery for lumbar disc herniation: a meta-analysis of efficacy and safety
Objective: Minimally invasive treatment plays a pivotal role in the management of lumbar disc herniation (LDH). Owing to its benefits, including reduced trauma, accelerated recovery, and decreased incidence of complications, it has progressively emerged as the primary approach for treating this condition. The objective of this study was to compare the outcomes observed in patients who underwent various minimally invasive surgical techniques for the treatment of LDH. Study design: Systematic reviews and meta-analyses. Methods: A systematic review was conducted to evaluate and compare the effectiveness of various minimally invasive treatment options for LDH, including percutaneous transforaminal endoscopic discectomy (PTED), microendoscopic discectomy (MED), microscopic discectomy (MD), percutaneous endoscopic interlaminar discectomy (PEID), endoscopic discectomy (ED), full-endoscopic discectomy (FED), percutaneous endoscopic lumbar discectomy (PELD), and PELD combined with platelet-rich plasma (PRP). The outcomes assessed included visual analog scores (VAS) for leg pain and back pain, Japanese Orthopedic Association scores, the Oswestry Disability Index (ODI), 36 physical functioning and bodily pain scores, the EuroQol five-dimensional score, the numeric pain score, the duration of surgery, and the relative risk of reoperation. The collected data were analyzed via a random effects meta-analysis approach. Results: This review analyzed 22 comparative studies with 4068 patients. Compared to MED, PTED had a shorter operative time (64.19 minutes vs. MED’s 66.61 minutes; not significant), less intraoperative blood loss (16.97 vs. 28.55; P < 0.001), and a shorter hospital stay (4.92 days vs. 6.71 days; P < 0.001). MED was associated with a lower postoperative recurrence rate (3.69% vs. 6.08% for PTED). Compared with PTED, PEID was associated with lower ODI (12.69 vs. 15.39; P = 0.77) and VAS scores (1.38 vs. 1.46; P = 0.42). MD significantly decreased intraoperative blood loss (48.63 vs. 64.4 in the ED) and operative time (85.38 vs. 114.65). The combination of PELD and PRP injections provided pain relief and reduced recurrence. Conclusion: Different minimally invasive surgeries for LDH have unique benefits. PTED has advantages in terms of operative time, blood loss, and length of hospital stay. However, there is a risk of nerve damage and cerebrospinal fluid leakage. The recurrence rate of MED is low. PEID is associated with lower ODI and VAS scores. MD reduces blood loss and operative time. The combination of PELD and PRP injections provides a new therapeutic direction for the treatment of LDH by relieving pain, reducing recurrence, improving patient satisfaction, and possibly promoting disc repair.
- 20 March 2025
- Published by SAGE Publications in The American Journal of Sports Medicine
- Vol. 53 (6) , 1428-1439
The Effect of Platelet-Rich Plasma on Synovial Fibrosis and Cartilage Degeneration in Knee Osteoarthritis
Background: Synovial fibrosis is a prevalent pathological feature of osteoarthritis and a primary contributor to joint pain and stiffness. Studies indicate that platelet-rich plasma (PRP) is rich in growth factors and cytokines, exhibiting anti-inflammatory, anti-apoptotic, chemotactic, and proliferative properties that can facilitate tissue repair. However, little is known about its effect on synovial fibrosis in knee osteoarthritis (KOA). Purpose: To determine the effect of PRP on synovial fibrosis and cartilage degeneration in KOA. Study Design: Controlled laboratory study. Method: Anterior cruciate ligament transection was performed to induce KOA in male Sprague-Dawley rats, and then rats were randomly assigned to 4 different groups: sham operation, KOA only, KOA treated with phosphate-buffered saline (PBS), and KOA treated with PRP. Synovial collagen fiber deposition was observed using Masson and Sirius red staining, and synovial inflammation was assessed using hematoxylin and eosin (H&E) staining. Moreover, immunohistochemistry was conducted to analyze the expression of synovial fibrosis–related factors including PLOD2, COL1A1, TIMP1, TGF-β1, and α-SMA. KOA severity and articular cartilage degradation were assessed using micro–computed tomography (micro-CT), safranin O–fast green staining, H&E staining, immunohistochemistry, and the Osteoarthritis Research Society International (OARSI) criteria. A quantitative analysis of growth factors (platelet-derived growth factor, IGF-1, epidermal growth factor, TGF-β1, fibroblast growth factor, and endothelial growth factor) in activated PRP was performed using enzyme-linked immunosorbent assay. Results: Micro-CT imaging and histological staining showed that the KOA model had been successfully established. Compared with the KOA and PBS groups, Masson staining and Sirius red staining results showed that PRP aggravated the degree of synovial fibrosis, which was consistent with the results of immunohistochemistry analysis. Immunohistochemistry analysis showed that PRP promoted the protein expression of PLOD2, COL1A1, TIMP1, TGF-β1, and α-SMA, indicating that the degree of fibrosis was aggravated. However, the PRP group showed lower OARSI and synovitis scores, as well as attenuated abnormal tibial subchondral bone remodeling, suggesting that PRP inhibited further cartilage degeneration and synovial inflammation and improved the subchondral bone microarchitecture. Conclusion: PRP may aggravate KOA synovial fibrosis, but it still has an inhibitory effect on cartilage degeneration and abnormal subchondral bone remodeling. Clinical Relevance: Synovial fibrosis is a significant pathological feature in KOA that is closely linked to clinical symptoms like joint pain and stiffness. This study offers insights into enhancing the effectiveness of PRP therapy for patients with KOA.
- 20 March 2025
- Published by SAGE Publications in The American Journal of Sports Medicine
- Vol. 53 (6) , 1428-1439
The Effect of Platelet-Rich Plasma on Synovial Fibrosis and Cartilage Degeneration in Knee Osteoarthritis
Background: Synovial fibrosis is a prevalent pathological feature of osteoarthritis and a primary contributor to joint pain and stiffness. Studies indicate that platelet-rich plasma (PRP) is rich in growth factors and cytokines, exhibiting anti-inflammatory, anti-apoptotic, chemotactic, and proliferative properties that can facilitate tissue repair. However, little is known about its effect on synovial fibrosis in knee osteoarthritis (KOA). Purpose: To determine the effect of PRP on synovial fibrosis and cartilage degeneration in KOA. Study Design: Controlled laboratory study. Method: Anterior cruciate ligament transection was performed to induce KOA in male Sprague-Dawley rats, and then rats were randomly assigned to 4 different groups: sham operation, KOA only, KOA treated with phosphate-buffered saline (PBS), and KOA treated with PRP. Synovial collagen fiber deposition was observed using Masson and Sirius red staining, and synovial inflammation was assessed using hematoxylin and eosin (H&E) staining. Moreover, immunohistochemistry was conducted to analyze the expression of synovial fibrosis–related factors including PLOD2, COL1A1, TIMP1, TGF-β1, and α-SMA. KOA severity and articular cartilage degradation were assessed using micro–computed tomography (micro-CT), safranin O–fast green staining, H&E staining, immunohistochemistry, and the Osteoarthritis Research Society International (OARSI) criteria. A quantitative analysis of growth factors (platelet-derived growth factor, IGF-1, epidermal growth factor, TGF-β1, fibroblast growth factor, and endothelial growth factor) in activated PRP was performed using enzyme-linked immunosorbent assay. Results: Micro-CT imaging and histological staining showed that the KOA model had been successfully established. Compared with the KOA and PBS groups, Masson staining and Sirius red staining results showed that PRP aggravated the degree of synovial fibrosis, which was consistent with the results of immunohistochemistry analysis. Immunohistochemistry analysis showed that PRP promoted the protein expression of PLOD2, COL1A1, TIMP1, TGF-β1, and α-SMA, indicating that the degree of fibrosis was aggravated. However, the PRP group showed lower OARSI and synovitis scores, as well as attenuated abnormal tibial subchondral bone remodeling, suggesting that PRP inhibited further cartilage degeneration and synovial inflammation and improved the subchondral bone microarchitecture. Conclusion: PRP may aggravate KOA synovial fibrosis, but it still has an inhibitory effect on cartilage degeneration and abnormal subchondral bone remodeling. Clinical Relevance: Synovial fibrosis is a significant pathological feature in KOA that is closely linked to clinical symptoms like joint pain and stiffness. This study offers insights into enhancing the effectiveness of PRP therapy for patients with KOA.